Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.78 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.78 |
| ▸ | CLK1 | P49759 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11279344 | 0.88 | DYRK1A (1.00) | DYRK1AFSCN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10935898 | 0.86 | DYRK1A (0.59) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL9891796 | 0.84 | NPC1 (0.59) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL9892912 | 0.84 | RAB9A (0.68) | DYRK1AFSCN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9891513 | 0.84 | NPC1 (0.57) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL130572 | 0.83 | DYRK1A (1.00) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL31060991 | 0.83 | DYRK1A (1.00) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL16992945 | 0.83 | DYRK1A (1.00) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL4501407 | 0.82 | DYRK1A (0.71) | DYRK1AFSCN1CLK1NPC1RAB9A | |
| SCHEMBL856499 | 0.82 | DYRK1A (1.00) | DYRK1AFSCN1CLK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | DYRK1A 2191/4885FSCN1 4466/4885CLK1 2481/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | DYRK1A 1974/4885FSCN1 4799/4885CLK1 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.